This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks

CAMBRIDGE, Mass. ( TheStreet) -- Aveo Oncology (AVEO - Get Report) shares are down 23% to $5.74 in Tuesday's trading following the release of an FDA review of its kidney cancer drug tivozanib. An FDA advisory panel will be reviewing tivozanib on Thursday.

Frankly, I'm surprised at the ferocity of selling in Aveo this morning. FDA raised concerns about the negative survival data in the tivozanib phase III trial, but investors knew this was going to be a significant issue for the agency and a big debating point during Thursday's panel.

Here's the key voting question for Thursday's tivozanib panel, as proposed by FDA:

Given the uncertainty in overall survival, and availability of multiple therapies, is another trial needed to better characterize the risk:benefit profile of tivozanib before approval can be considered?

The suggestion that FDA may want Aveo to conduct a second clinical trial of tivozanib is probably what's freaking out investors most this morning. The scare might be justified. Here's what FDA says about a meeting with Aveo held in May 2012, right before the company submitted tivozanib for approval:

A pre-NDA meeting was held in May 2012. Here, the FDA expressed concern about the adverse trend in overall survival in the single phase 3 trial and recommended that the sponsor conduct a second adequately powered randomized trial in a population comparable to that in the U.S.

Remember, Aveo only enrolled 40 patients out of 517 in the tivozanib trial from centers in Western Europe and North America. Later in the review, FDA says it's "unclear whether the patients in this study were representative of those in the U.S."

FDA's review of tivozanib was only 13 pages long, relatively brief and straightforward. As we knew already, tivozanib demonstrated a statistically significant improvement in progression-free survival over Onyx Pharmaceuticals' (ONXX) Nexavar, but overall survival in the tivozanib arm was shorter than in the Nexavar arm. This PFS-OS conundrum will be the focal point of Thursday's FDA advisory panel.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
AVEO $1.51 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs